American Century Companies Inc. Increases Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

American Century Companies Inc. increased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 9.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,140,705 shares of the specialty pharmaceutical company’s stock after acquiring an additional 95,777 shares during the period. American Century Companies Inc. owned approximately 2.07% of Supernus Pharmaceuticals worth $41,248,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SUPN. Barclays PLC raised its stake in shares of Supernus Pharmaceuticals by 88.3% in the third quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock worth $3,393,000 after purchasing an additional 51,005 shares during the last quarter. Geode Capital Management LLC raised its position in Supernus Pharmaceuticals by 5.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after buying an additional 74,438 shares during the last quarter. Franklin Resources Inc. lifted its stake in Supernus Pharmaceuticals by 7.6% during the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock valued at $987,000 after acquiring an additional 2,121 shares during the period. Empowered Funds LLC purchased a new stake in shares of Supernus Pharmaceuticals in the 4th quarter valued at $1,498,000. Finally, Smartleaf Asset Management LLC increased its stake in shares of Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 870 shares during the period.

Insider Activity at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 700 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total value of $27,734.00. Following the completion of the sale, the vice president now directly owns 10,149 shares in the company, valued at $402,103.38. The trade was a 6.45 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Jonathan Rubin sold 927 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the transaction, the senior vice president now owns 7,853 shares in the company, valued at $307,444.95. This trade represents a 10.56 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,104 shares of company stock worth $440,263 in the last 90 days. Corporate insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Stock Performance

SUPN stock opened at $32.42 on Friday. The firm’s fifty day moving average is $35.26 and its 200 day moving average is $35.02. The firm has a market cap of $1.81 billion, a PE ratio of 30.30 and a beta of 0.83. Supernus Pharmaceuticals, Inc. has a one year low of $25.53 and a one year high of $40.28.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on SUPN. StockNews.com downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday. Cantor Fitzgerald restated a “neutral” rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.